- Home
- JBIO
JBIO
JADE BIOSCIENCES INC
as 07-25-2025 4:00pm EST
Stocks
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
| Founded: | 2024 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 290.1M | IPO Year: | N/A |
| Target Price: | $15.50 | AVG Volume (30 days): | 397.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -18.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.61 - $13.50 | Next Earning Date: | 08-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest JADE BIOSCIENCES INC News
JBIO Breaking Stock News: Dive into JBIO Ticker-Specific Updates for Smart Investing
Yahoo Finance
16 days ago
The early winner in the 'Dexit' war for corporate relocations: Nevada
GlobeNewswire
18 days ago
Jade Biosciences to Participate in Two Upcoming Investor Conferences
GlobeNewswire
25 days ago
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
Barchart
a month ago
2 Small-Cap Stocks Under $10 to Buy With Big Potential
GlobeNewswire
2 months ago
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
GlobeNewswire
2 months ago
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress
GlobeNewswire
2 months ago
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
2 months ago
Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference
Compare JBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JBIO JADE BIOSCIENCES INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.